Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Muscle disorders

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44412   clinical trials with a EudraCT protocol, of which   7421   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    558 result(s) found for: Muscle disorders. Displaying page 1 of 28.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-000141-31 Sponsor Protocol Number: ISRCTN30952488 Start Date*: 2016-08-30
    Sponsor Name:London School of Hygiene and Tropical Medicine
    Full Title: A SERIES OF RANDOMISED CONTROLLED N-of 1 TRIALS IN PATIENTS WHO HAVE DISCONTINUED OR WISH TO DISCONTINUE STATIN USE DUE TO MUSCLE-RELATED SYMPTOMS TO ASSESS IF ATORVASTATIN TREATMENT CAUSES MORE MU...
    Medical condition: myalgia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10028411 Myalgia PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001597-16 Sponsor Protocol Number: none Start Date*: 2018-07-18
    Sponsor Name:Sitnikova Victoria
    Full Title: Efficacy of botulinum toxin in treating temporomandibular disorders
    Medical condition: Patients are diagnosed TMD (temporomandibular disorder) according to DC/TMD international consortium: myalgia, local myalgia, myofascial pain, myofascial pain with referral.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10028323 Muscle pains HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003359-33 Sponsor Protocol Number: MABS06 Start Date*: 2023-06-21
    Sponsor Name:MUMC
    Full Title: Assess efficacy of intra-arterial autologous myogenic stem cell therapy for m.3243A>G mutation carriers
    Medical condition: Mitochondrial myopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10027710 Mitochondrial myopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-005942-35 Sponsor Protocol Number: 1413 Start Date*: 2007-03-14
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Simvastatin therapy in IBM
    Medical condition: inclusion body myositis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10028641 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004608-32 Sponsor Protocol Number: DYN101-C102 Start Date*: Information not available in EudraCT
    Sponsor Name:Dynacure
    Full Title: A Phase 1/2, multicenter, open-label, dose-confirmation trial to evaluate the safety and preliminary efficacy of DYN101 in subjects 2 to 17 years of age with centronuclear myopathy caused by mutati...
    Medical condition: Centronuclear myopathy (CNM), in subjects 2 to 17 years of age (all ages inclusive)caused by mutations in the myotubularin1 (MTM1) or dynamin 2 (DNM2) gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10028640 Myopathies HLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004089-13 Sponsor Protocol Number: KLF/K/019811 Start Date*: 2012-05-04
    Sponsor Name:Cassella-med GmbH & Co. KG
    Full Title: Placebo-controlled exploratory pilot study to investigate the effect and onset of action of Traumaplant® for delayed onset muscle soreness.
    Medical condition: delayed onset muscle soreness (DOMS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10028332 Muscle soreness LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005900-15 Sponsor Protocol Number: P051204 Start Date*: 2007-07-26
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: FORCE : rituximab (anticorps monoclonal anti-CD20 dépléteur des lymphocytes B) pour le traitement des myopathies inflammatoires réfractaires avec auto-anticorps spécifiques et des myasthénies génér...
    Medical condition: Myopathies inflammatoires réfractaires associés à des auto-AC spécifiques Myasthénies généralisées
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028641 Myopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024659-10 Sponsor Protocol Number: 2010-024659-10 Start Date*: 2011-08-03
    Sponsor Name:Rigshospitalet
    Full Title: Can stimulation of the nNOS system in muscle disease with nNOS insufficiency improve heart and skeletal muscle function and cognition?
    Medical condition: Muscular dystrophy with nNOS insufficiency
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10028301 Muscle disorder NOS LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-000391-15 Sponsor Protocol Number: AIFA-2016-02364869 Start Date*: 2018-06-05
    Sponsor Name:Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia
    Full Title: Multicentric, open-label, prospective study of subcutaneous tocilizumab in adult patients with refractory myositis
    Medical condition: Myositis (dermatomyositis [DM] or polymyositis [PM])
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10028653 Myositis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10036102 Polymyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001205-27 Sponsor Protocol Number: ABR35884 Start Date*: 2011-08-04
    Sponsor Name:
    Full Title: The effect of fibrate therapy in two patients with neutral lipid storage disease with myopathy (NLSDM).
    Medical condition: Neutral lipid storage disease with myopathy
    Disease: Version SOC Term Classification Code Term Level
    13.1 10007541 - Cardiac disorders 10007636 Cardiomyopathy PT
    13.1 10027433 - Metabolism and nutrition disorders 10013317 Lipid metabolism disorders HLGT
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10028641 Myopathy PT
    Population Age: Gender:
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020521-40 Sponsor Protocol Number: DG-EF 01/09 Start Date*: 2010-06-21
    Sponsor Name:EPIFARMA S.R.L.
    Full Title: Evaluation of therapeutic equivalence of diclofenac gel 1% formulation compared to Voltaren emulGel 1% gel in subjects with traumatic pathology: a double blind, randomized, phase III multicentre st...
    Medical condition: Painful and traumatic inflammation of the joints, muscles, tendons and ligaments.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028393 HLGT
    9.1 10023213 HLGT
    9.1 10043237 HLGT
    9.1 10028302 HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004140-32 Sponsor Protocol Number: PRP-MUSCULO-2014-01 Start Date*: 2014-04-28
    Sponsor Name:Unidad de Cirugia Artroscópica
    Full Title: CLINICAL STUDY TO ASSES THERAPEUTIC USE OF PLATELET RICH PLASMA IN ACUTE MUSCLE INJURIES IN ELITE ATHLETES"
    Medical condition: Acute Muscle Injury Type 3A-3B (Munich classification) or type II (Classification of Otto Chan), confirmed by radiological diagnosis and clinical agreement.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10028391 Musculoskeletal pain PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004089-33 Sponsor Protocol Number: DYN101-C101 Start Date*: 2019-08-27
    Sponsor Name:Dynacure SAS
    Full Title: A Phase 1/2 trial on the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of DYN101 in patients ≥ 16 years of age with centronuclear myopathies caused by mutations ...
    Medical condition: Centronuclear myopathies (CNMs) in patients ≥ 16 years of age with mutations in DNM2 or MTM1
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DK (Prematurely Ended) BE (Prematurely Ended) NL (Ongoing) DE (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-002315-98 Sponsor Protocol Number: MedicalcannabisMSSCI2018 Start Date*: 2018-12-06
    Sponsor Name:Aarhus Universitetshospital
    Full Title: The effect of medical cannabis on neuropathic pain and spasticity in patients with Multiple Sclerosis and in patients with spinal cord injury. A multicenter national placebo-controlled trial
    Medical condition: Central neuropathic pain and spasticity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028335 Muscle spasticity PT
    20.0 10029205 - Nervous system disorders 10077975 Central neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-003644-12 Sponsor Protocol Number: 2014-003644-12 Start Date*: 2015-02-20
    Sponsor Name:Neuromuscular Research Unit, Rigshospitalet
    Full Title: The effect of Triheptanoin in adults with McArdle Disease (Glycogen Storage Disease Type V)
    Medical condition: McArdle Disease Also called: Glycogen Storage Disease Type V or Myophosphorylase Deficiency
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10026970 McArdles disease LLT
    19.0 10010331 - Congenital, familial and genetic disorders 10026969 McArdle's disease LLT
    19.0 10010331 - Congenital, familial and genetic disorders 10018462 Glycogen storage disease type V PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011184-36 Sponsor Protocol Number: 08/0169 Start Date*: 2009-07-14
    Sponsor Name:University College London-Joint UCLH/UCL Biomedical (R&D) Unit
    Full Title: A Phase II Randomised, Double-Blind, Placebo Controlled, Cross-Over Study to Investigate the Efficacy of Mexiletine in Patients with Non-Dystrophic Myotonia.
    Medical condition: Non-Dystrophic Myotonia (NDM). Non-dystrophic myotonias are a group of rare neuromuscular disorders that cause episodes of muscle stiffness (known as myotonia) and paralysis. Predominantly the musc...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029317 Neuromuscular disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001730-19 Sponsor Protocol Number: v1-2 Start Date*: 2022-02-24
    Sponsor Name:Medical Univerity of Vienna
    Full Title: Hormones and Muscle – Unravelling the metabolic pathways of endocrine myopathies A translational magnetic resonance spectroscopy and imaging pilot study
    Medical condition: Hypothyroidism Hypoparathyroidism
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003251-74 Sponsor Protocol Number: 62/2008/U/Sper Start Date*: 2008-06-24
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: ROLE OF TESTOSTERONE AND ITS METABOLITE DIHYDROTESTOSTERONE ON METABOLISM AND ON MUSCLE STRENGTH IN SUBJECTS AFFECTED BY GENEDER IDENTITY DISORDER (GID) (FtM TRANSSEXUALS)
    Medical condition: GENDER IDENTITY DISORDER (GID) (FtM TRANSSEXUALS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061976 Gender identity disorder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003771-18 Sponsor Protocol Number: GWSP08258 Start Date*: 2013-08-06
    Sponsor Name:GW Pharma Ltd.
    Full Title: The efficacy, safety and tolerability of Sativex as an adjunctive treatment to existing anti-spasticity medications in children aged 8 to 18 years with spasticity due to cerebral palsy or traumatic...
    Medical condition: Spasticity due to cerebral palsy (CP) or traumatic central nervous system injury.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10028335 Muscle spasticity PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-005202-98 Sponsor Protocol Number: 80202135IIM2001 Start Date*: 2022-11-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Nipocalimab in Participants with Active Idiopathic Inflammatory Myo...
    Medical condition: Active Idiopathic Inflammatory Myopathies (IIM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10028640 Myopathies HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 16 08:34:16 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA